Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis
Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in he...
Ausführliche Beschreibung
Autor*in: |
---|
Format: |
E-Artikel |
---|
Erschienen: |
Oxford, UK: Munksgaard International Publishers ; 2003 |
---|
Schlagwörter: |
---|
Umfang: |
Online-Ressource |
---|
Reproduktion: |
2003 ; Blackwell Publishing Journal Backfiles 1879-2005 |
---|---|
Übergeordnetes Werk: |
In: Journal of oral pathology & medicine - Oxford [u.a.] : Wiley-Blackwell, 1972, 32(2003), 3, Seite 0 |
Übergeordnetes Werk: |
volume:32 ; year:2003 ; number:3 ; pages:0 |
Links: |
---|
DOI / URN: |
10.1034/j.1600-0714.2003.00012.x |
---|
Katalog-ID: |
NLEJ243035608 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLEJ243035608 | ||
003 | DE-627 | ||
005 | 20230506164441.0 | ||
007 | cr uuu---uuuuu | ||
008 | 120427s2003 xx |||||o 00| ||und c | ||
024 | 7 | |a 10.1034/j.1600-0714.2003.00012.x |2 doi | |
035 | |a (DE-627)NLEJ243035608 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
245 | 1 | 0 | |a Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis |
264 | 1 | |a Oxford, UK |b Munksgaard International Publishers |c 2003 | |
300 | |a Online-Ressource | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. | ||
533 | |d 2003 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2003|||||||||| | ||
650 | 4 | |a HNSCC | |
700 | 1 | |a Logullo, Angela F. |4 oth | |
700 | 1 | |a Nonogaki, Suely |4 oth | |
700 | 1 | |a Miguel, Roberto E. |4 oth | |
700 | 1 | |a Kowalski, Luiz P. |4 oth | |
700 | 1 | |a Nishimoto, Inês N. |4 oth | |
700 | 1 | |a Pasini, Fátima S. |4 oth | |
700 | 1 | |a Federico, Miriam H. H. |4 oth | |
700 | 1 | |a Brentani, Ricardo R. |4 oth | |
700 | 1 | |a Brentani, M. Mitzi |4 oth | |
773 | 0 | 8 | |i In |t Journal of oral pathology & medicine |d Oxford [u.a.] : Wiley-Blackwell, 1972 |g 32(2003), 3, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243927231 |w (DE-600)2026385-5 |x 1600-0714 |7 nnns |
773 | 1 | 8 | |g volume:32 |g year:2003 |g number:3 |g pages:0 |
856 | 4 | 0 | |u http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a ZDB-1-DJB | ||
912 | |a GBV_NL_ARTICLE | ||
951 | |a AR | ||
952 | |d 32 |j 2003 |e 3 |h 0 |
matchkey_str |
article:16000714:2003----::rnfrigrwhatrtfepesoihaadekqaoselacnmp |
---|---|
hierarchy_sort_str |
2003 |
publishDate |
2003 |
allfields |
10.1034/j.1600-0714.2003.00012.x doi (DE-627)NLEJ243035608 DE-627 ger DE-627 rakwb Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis Oxford, UK Munksgaard International Publishers 2003 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. 2003 Blackwell Publishing Journal Backfiles 1879-2005 |2003|||||||||| HNSCC Logullo, Angela F. oth Nonogaki, Suely oth Miguel, Roberto E. oth Kowalski, Luiz P. oth Nishimoto, Inês N. oth Pasini, Fátima S. oth Federico, Miriam H. H. oth Brentani, Ricardo R. oth Brentani, M. Mitzi oth In Journal of oral pathology & medicine Oxford [u.a.] : Wiley-Blackwell, 1972 32(2003), 3, Seite 0 Online-Ressource (DE-627)NLEJ243927231 (DE-600)2026385-5 1600-0714 nnns volume:32 year:2003 number:3 pages:0 http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2003 3 0 |
spelling |
10.1034/j.1600-0714.2003.00012.x doi (DE-627)NLEJ243035608 DE-627 ger DE-627 rakwb Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis Oxford, UK Munksgaard International Publishers 2003 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. 2003 Blackwell Publishing Journal Backfiles 1879-2005 |2003|||||||||| HNSCC Logullo, Angela F. oth Nonogaki, Suely oth Miguel, Roberto E. oth Kowalski, Luiz P. oth Nishimoto, Inês N. oth Pasini, Fátima S. oth Federico, Miriam H. H. oth Brentani, Ricardo R. oth Brentani, M. Mitzi oth In Journal of oral pathology & medicine Oxford [u.a.] : Wiley-Blackwell, 1972 32(2003), 3, Seite 0 Online-Ressource (DE-627)NLEJ243927231 (DE-600)2026385-5 1600-0714 nnns volume:32 year:2003 number:3 pages:0 http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2003 3 0 |
allfields_unstemmed |
10.1034/j.1600-0714.2003.00012.x doi (DE-627)NLEJ243035608 DE-627 ger DE-627 rakwb Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis Oxford, UK Munksgaard International Publishers 2003 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. 2003 Blackwell Publishing Journal Backfiles 1879-2005 |2003|||||||||| HNSCC Logullo, Angela F. oth Nonogaki, Suely oth Miguel, Roberto E. oth Kowalski, Luiz P. oth Nishimoto, Inês N. oth Pasini, Fátima S. oth Federico, Miriam H. H. oth Brentani, Ricardo R. oth Brentani, M. Mitzi oth In Journal of oral pathology & medicine Oxford [u.a.] : Wiley-Blackwell, 1972 32(2003), 3, Seite 0 Online-Ressource (DE-627)NLEJ243927231 (DE-600)2026385-5 1600-0714 nnns volume:32 year:2003 number:3 pages:0 http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2003 3 0 |
allfieldsGer |
10.1034/j.1600-0714.2003.00012.x doi (DE-627)NLEJ243035608 DE-627 ger DE-627 rakwb Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis Oxford, UK Munksgaard International Publishers 2003 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. 2003 Blackwell Publishing Journal Backfiles 1879-2005 |2003|||||||||| HNSCC Logullo, Angela F. oth Nonogaki, Suely oth Miguel, Roberto E. oth Kowalski, Luiz P. oth Nishimoto, Inês N. oth Pasini, Fátima S. oth Federico, Miriam H. H. oth Brentani, Ricardo R. oth Brentani, M. Mitzi oth In Journal of oral pathology & medicine Oxford [u.a.] : Wiley-Blackwell, 1972 32(2003), 3, Seite 0 Online-Ressource (DE-627)NLEJ243927231 (DE-600)2026385-5 1600-0714 nnns volume:32 year:2003 number:3 pages:0 http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2003 3 0 |
allfieldsSound |
10.1034/j.1600-0714.2003.00012.x doi (DE-627)NLEJ243035608 DE-627 ger DE-627 rakwb Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis Oxford, UK Munksgaard International Publishers 2003 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. 2003 Blackwell Publishing Journal Backfiles 1879-2005 |2003|||||||||| HNSCC Logullo, Angela F. oth Nonogaki, Suely oth Miguel, Roberto E. oth Kowalski, Luiz P. oth Nishimoto, Inês N. oth Pasini, Fátima S. oth Federico, Miriam H. H. oth Brentani, Ricardo R. oth Brentani, M. Mitzi oth In Journal of oral pathology & medicine Oxford [u.a.] : Wiley-Blackwell, 1972 32(2003), 3, Seite 0 Online-Ressource (DE-627)NLEJ243927231 (DE-600)2026385-5 1600-0714 nnns volume:32 year:2003 number:3 pages:0 http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2003 3 0 |
source |
In Journal of oral pathology & medicine 32(2003), 3, Seite 0 volume:32 year:2003 number:3 pages:0 |
sourceStr |
In Journal of oral pathology & medicine 32(2003), 3, Seite 0 volume:32 year:2003 number:3 pages:0 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
HNSCC |
isfreeaccess_bool |
false |
container_title |
Journal of oral pathology & medicine |
authorswithroles_txt_mv |
Logullo, Angela F. @@oth@@ Nonogaki, Suely @@oth@@ Miguel, Roberto E. @@oth@@ Kowalski, Luiz P. @@oth@@ Nishimoto, Inês N. @@oth@@ Pasini, Fátima S. @@oth@@ Federico, Miriam H. H. @@oth@@ Brentani, Ricardo R. @@oth@@ Brentani, M. Mitzi @@oth@@ |
publishDateDaySort_date |
2003-01-01T00:00:00Z |
hierarchy_top_id |
NLEJ243927231 |
id |
NLEJ243035608 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ243035608</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506164441.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2003 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1034/j.1600-0714.2003.00012.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ243035608</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Munksgaard International Publishers</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2003</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2003||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HNSCC</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Logullo, Angela F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nonogaki, Suely</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miguel, Roberto E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kowalski, Luiz P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishimoto, Inês N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pasini, Fátima S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Federico, Miriam H. H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brentani, Ricardo R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brentani, M. Mitzi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of oral pathology & medicine</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1972</subfield><subfield code="g">32(2003), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927231</subfield><subfield code="w">(DE-600)2026385-5</subfield><subfield code="x">1600-0714</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">2003</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243927231 |
format |
electronic Article |
delete_txt_mv |
keep |
collection |
NL |
publishPlace |
Oxford, UK |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1600-0714 |
topic_title |
Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis HNSCC |
publisher |
Munksgaard International Publishers |
publisherStr |
Munksgaard International Publishers |
topic |
misc HNSCC |
spellingShingle |
misc HNSCC Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis |
topic_unstemmed |
misc HNSCC |
topic_browse |
misc HNSCC |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
a f l af afl s n sn r e m re rem l p k lp lpk i n n in inn f s p fs fsp m h h f mhh mhhf r r b rr rrb m m b mm mmb |
hierarchy_parent_title |
Journal of oral pathology & medicine |
hierarchy_parent_id |
NLEJ243927231 |
hierarchy_top_title |
Journal of oral pathology & medicine |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)NLEJ243927231 (DE-600)2026385-5 |
title |
Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis |
ctrlnum |
(DE-627)NLEJ243035608 |
title_full |
Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis |
journal |
Journal of oral pathology & medicine |
journalStr |
Journal of oral pathology & medicine |
isOA_bool |
false |
recordtype |
marc |
publishDateSort |
2003 |
contenttype_str_mv |
zzz |
container_start_page |
0 |
container_volume |
32 |
physical |
Online-Ressource |
format_se |
Elektronische Aufsätze |
doi_str_mv |
10.1034/j.1600-0714.2003.00012.x |
title_sort |
transforming growth factor β1 (tgfβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis |
title_auth |
Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis |
abstract |
Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. |
abstractGer |
Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. |
abstract_unstemmed |
Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. |
collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
container_issue |
3 |
title_short |
Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis |
url |
http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x |
remote_bool |
true |
author2 |
Logullo, Angela F. Nonogaki, Suely Miguel, Roberto E. Kowalski, Luiz P. Nishimoto, Inês N. Pasini, Fátima S. Federico, Miriam H. H. Brentani, Ricardo R. Brentani, M. Mitzi |
author2Str |
Logullo, Angela F. Nonogaki, Suely Miguel, Roberto E. Kowalski, Luiz P. Nishimoto, Inês N. Pasini, Fátima S. Federico, Miriam H. H. Brentani, Ricardo R. Brentani, M. Mitzi |
ppnlink |
NLEJ243927231 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth oth |
doi_str |
10.1034/j.1600-0714.2003.00012.x |
up_date |
2024-07-06T04:03:21.128Z |
_version_ |
1803800911417442304 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ243035608</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506164441.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2003 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1034/j.1600-0714.2003.00012.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ243035608</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Munksgaard International Publishers</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Transforming growth factor β1 (TGFβ1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFβ1 responsiveness is a critical step in epithelial carcinogenesis.Objective: To investigate the prognostic relevance of TGFβ1 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methods: TGFβ1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFβ-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells.Results: TGFβ1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFβ1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P ≤ 0.001). TGFβ1 was also not related to 5 years survival (Kaplan–Meier). Strong and diffuse expression of TGFβ-RII was identified in 19/20 cases regardless of TGFβ1 immunoreactivity. Out of 17 TGFβ1-positive oral cavity/oropharynx tumors, only nine expressed TGFβ-RI suggesting a disruption of the TGFβ1 pathway. We conclude that TGFβ1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2003</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2003||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HNSCC</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Logullo, Angela F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nonogaki, Suely</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miguel, Roberto E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kowalski, Luiz P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishimoto, Inês N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pasini, Fátima S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Federico, Miriam H. H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brentani, Ricardo R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brentani, M. Mitzi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of oral pathology & medicine</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1972</subfield><subfield code="g">32(2003), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927231</subfield><subfield code="w">(DE-600)2026385-5</subfield><subfield code="x">1600-0714</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1034/j.1600-0714.2003.00012.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">2003</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
score |
7.4010057 |